Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKN3R9)

• Drug Name: AH6809 Drug Info
• Synonyms: AH 6809; AH-6809

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 119461
  ChEBI ID: CHEBI:95289
  CAS Number: CAS 33458-93-4
  TTD Drug ID: DMKN3R9

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin E2 receptor EP1 (PTGER1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AS-013	DMD7XWS	Thrombosis	DB61-GB90	Phase 3	[4]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[3]
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[5]
ZD6416	DM46JIR	Pain	MG30-MG3Z	Discontinued in Phase 2	[6]
ONO-8130	DMBDCL4	Pollakiuria	MF50.1	Terminated	[7]
ONO-8711	DM2VRK7	Pain	MG30-MG3Z	Terminated	[8]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[3]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[2]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[9]
M&B 28767	DMJQG82	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[5]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[11]
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[12]
Iloprost	DMVPZBE	Pulmonary arterial hypertension	BB01.0	Approved	[13]
Omidenepag isopropyl	DMUX7Z8	Glaucoma/ocular hypertension	9C61	Approved	[14]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[15]
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[10]
CP-533536	DMZEJLB	Osteoporosis	FB83.0	Phase 2	[16]
Taprenepag	DM1TSHL	Glaucoma/ocular hypertension	9C61	Phase 2	[17]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]

Drug(s) Targeting Prostaglandin D2 receptor (PTGDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[15]
Setipiprant	DMZ61IA	Asthma	CA23	Phase 3	[19]
QAW-039	DMPCFXN	Asthma	CA23	Phase 3	[20]
AMG 853	DM973N4	Asthma	CA23	Phase 2	[21]
ONO-4053	DMX4MVP	Allergic rhinitis	CA08.0	Phase 2	[22]
TS-022	DMMNXIW	Atopic dermatitis	EA80	Phase 2	[23]
S-555739	DMXDVNZ	Allergy	4A80-4A85	Phase 2	[24]
MK-1029	DM8ZTW7	Asthma	CA23	Phase 2	[25]
SAR-389644	DMA6O9R	Allergic rhinitis	CA08.0	Phase 1	[26]
192C86	DMQ8NTZ	Thrombosis	DB61-GB90	Phase 1	[27]

Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[10]
ONO-9054	DM5O6GC	Glaucoma/ocular hypertension	9C61	Phase 2	[28]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[10]
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[5]
DG041	DMVO9WM	Peripheral vascular disease	BD4Z	Discontinued in Phase 2	[29]
GR-63799X	DM13GK8	Asthma	CA23	Discontinued in Phase 1	[30]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[2]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[10]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[3]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin D2 receptor (PTGDR)	TTNVEIR	PD2R_HUMAN	Antagonist	[2]
Prostaglandin E2 receptor EP1 (PTGER1)	TTG1QMU	PE2R1_HUMAN	Antagonist	[3]
Prostaglandin E2 receptor EP2 (PTGER2)	TT1ZAVI	PE2R2_HUMAN	Antagonist	[2]
Prostaglandin E2 receptor EP3 (PTGER3)	TTPNGDE	PE2R3_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1896).
• [2] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [3] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
• [4] Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
• [5] Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
• [6] The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
• [7] ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
• [8] Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
• [9] Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
• [10] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
• [12] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [13] Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
• [14] Clinical pipeline report, company report or official report of Santen Pharmaceutical.
• [15] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [16] Pfizer. Product Development Pipeline. March 31 2009.
• [17] A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
• [18] Clinical pipeline report, company report or official report of Tempest Therapeutics.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
• [21] Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
• [22] Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
• [23] Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
• [24] Clinical pipeline report, company report or official report of Shionogi (2011).
• [25] Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
• [26] US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
• [27] Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
• [28] IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
• [29] BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
• [30] Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.